Androgen deprivation therapy and future Alzheimer's disease risk

Journal of Clinical Oncology

Volumn 34, Issue 6, 2016, Pages 566-571

  Nead, Kevin T ^a,c   Gaskin, Greg ^a   Chester, Cariad ^b   Swisher McClure, Samuel ^c   Dudley, Joel T ^d   Leeper, Nicholas J ^b   Shah, Nigam H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; TREATMENT DURATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CURRENT PROCEDURAL TERMINOLOGY; ELECTRONIC HEALTH RECORD; INTERNATIONAL CLASSIFICATION OF DISEASES; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CURRENT PROCEDURAL TERMINOLOGY; ELECTRONIC HEALTH RECORDS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84964311292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.6266     Document Type: Article

References (40)

1. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365: 107-118, 2011
2. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
3. Shahinian VB, Kuo YF, Freeman JL, et al: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624, 2005
4. Shahani S, Braga-Basaria M, Basaria S: Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042-2049, 2008
5. Yoon FH, Gardner SL, Danjoux C, et al: Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol 180: 1438-1443, 2008; discussion 1443-1444
6. Pickles T, Agranovich A, Berthelet E, et al: British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative: Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94:362-367, 2002
7. Brand JS, Van Der Tweel I, Grobbee DE, et al: Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and metaanalysis of observational studies. Int J Epidemiol 40: 189-207, 2011
8. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006
9. Shahinian VB, Kuo YF, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
10. McGinty HL, Phillips KM, Jim HS, et al: Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. Support Care Cancer 22: 2271-2280, 2014
11. Nelson CJ, Lee JS, Gamboa MC, et al: Cognitive effects of hormone therapy inmen with prostate cancer: A review. Cancer 113:1097-1106, 2008
12. Hogervorst E, Bandelow S, Combrinck M, et al: Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 39: 1633-1639, 2004
13. Hogervorst E, Williams J, Budge M, et al: Serum total testosterone is lower in men with Alzheimer's disease. Neuroendocrinol Lett 22:163-168, 2001
14. Moffat SD, Zonderman AB, Metter EJ, et al: Free testosterone and risk for Alzheimer disease in older men. Neurology 62:188-193, 2004
15. Rosario ER, Chang L, Stanczyk FZ, et al: Agerelated testosterone depletion and the development of Alzheimer disease. JAMA 292:1431-1432, 2004
16. Cherrier MM, Matsumoto AM, Amory JK, et al: Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64:2063-2068, 2005
17. Frain L, Swanson D, Betensky R, et al: A reduced risk of Alzheimer's disease is associated with the majority of cancers in a national cohort of veterans. Alzheimers Dement, 9:4, 2013 (suppl; abstr P617)
18. LePendu P, Iyer SV, Bauer-Mehren A, et al: Pharmacovigilance using clinical notes. Clin Pharmacol Ther 93:547-555, 2013
19. Leeper NJ, Bauer-Mehren A, Iyer SV, et al: Practice-based evidence: Profiling the safety of cilostazol by text-mining of clinical notes. PLoS One 8:e63499, 2013
20. Shah NH, LePendu P, Bauer-Mehren A, et al: Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 10:e0124653, 2015
21. Cole TS, Frankovich J, Iyer S, et al: Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: A new model for EHR-based research. Pediatr Rheumatol Online J 11:45, 2013
22. Jung K, LePendu P, Iyer S, et al: Functional evaluation of out-of-the-box text-mining tools for data-mining tasks. J Am Med Inform Assoc 22: 121-131, 2015
23. Wu ST, Liu H, Li D, et al: Unified Medical Language System term occurrences in clinical notes: A large-scale corpus analysis. J Am Med Inform Assoc 19:e149-e156, 2012
24. Harkema H, Dowling JN, Thornblade T, et al: ConText: An algorithm for determining negation, experiencer, and temporal status from clinical reports. J Biomed Inform 42:839-851, 2009
25. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192-201, 2007
26. Stuart EA: Matching methods for causal inference: A review and a look forward. Stat Sci 25: 1-21, 2010
27. Newman AB, Fitzpatrick AL, Lopez O, et al: Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. JAm Geriatr Soc 53: 1101-1107, 2005
28. Luchsinger JA, Tang MX, Stern Y, et al: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635-641, 2001
29. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334-357, 2002
30. Morton RA, Jr.: Racial differences in adenocarcinoma of the prostate in North American men. Urology 44:637-645, 1994
31. Frakt AB: An observational study goes where randomized clinical trials have not. JAMA 313: 1091-1092, 2015
32. Vest RS, Pike CJ: Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav 63: 301-307, 2013
33. Gandy S, Almeida OP, Fonte J, et al: Chemical andropause and amyloid-beta peptide. JAMA 285: 2195-2196, 2001
34. Wang C, Jackson G, Jones TH, et al: Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34:1669-1675, 2011
35. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
36. Hu JC, Williams SB, O'Malley AJ, et al: Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 61:1119-1128, 2012
37. Hofman A, Ott A, Breteler MM, et al: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349:151-154, 1997
38. Kukull WA, Bowen JD: Dementia epidemiology. Med Clin North Am 86:573-590, 2002
39. Snowden JS, Thompson JC, Stopford CL, et al: The clinical diagnosis of early-onset dementias: Diagnostic accuracy and clinicopathological relationships. Brain 134:2478-2492, 2011
40. Beach TG, Monsell SE, Phillips LE, et al: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71:266-273, 2012